...
首页> 外文期刊>Clinical Biochemistry >Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis.
【24h】

Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis.

机译:金属蛋白酶衍生的II型胶原新表位CIIM的酶联免疫吸附测定(ELISAs)在患有严重放射照相的骨关节炎患者中可增加血清CIIM。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: In joint degenerative diseases, the collagens are degraded by matrix metalloproteinases and protein fragments are released to serum as potential biomarkers. METHODS: A collagen type II specific neoepitope, CIIM, was identified (...RDGAAG(1053)) by mass spectrometry. Two ELISAs against the neoepitope were developed. CIIM was measured in cartilage explants in the presence or absence of protease inhibitors. CIIM was measured in OA synovial fluid (n=51) and serum (n=156). Knee OA was graded by standard Kellgren-Lawrence (KL) score. RESULTS: The ELISAs showed good technical performance; CV%, <13%. CIIM release from cartilage explants was blocked by the MMP inhibitor. CIIM was detected in synovial fluid. Furthermore, serum CIIM levels were significantly higher (P<0.05) in those individuals with mild or severe OA than in those with no OA. CONCLUSION: We developed a new biomarker for joint degenerative diseases, which we demonstrated was derived from MMP-degraded type II collagen.
机译:目的:在关节退行性疾病中,胶原蛋白被基质金属蛋白酶降解,蛋白质片段作为潜在的生物标记物释放到血清中。方法:通过质谱鉴定了II型胶原特异性新表位CIIM(... RDGAAG(1053))。开发了两种针对新表位的ELISA。在有或没有蛋白酶抑制剂的情况下,在软骨外植体中测量CIIM。在OA滑液(n = 51)和血清(n = 156)中测量CIIM。膝盖OA通过标准的Kellgren-Lawrence(KL)评分进行评分。结果:ELISAs显示出良好的技术性能。 CV%,<13%。 MMP抑制剂阻止了软骨外植体的CIIM释放。在滑液中检测到CIIM。此外,轻度或重度OA患者的血清CIIM水平显着高于无OA的患者(P <0.05)。结论:我们开发了一种新的用于关节退行性疾病的生物标志物,我们证明了它来自MMP降解的II型胶原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号